Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.

Peter M. Voorhees, MD, Cristina Gasparetto, MD, Kristy L. Richards, PhD, MD, Reynaldo Garcia, RN, OCN, John S. Strader, Madlyn Ferraro, RN, OCN, CCRC, Jennifer MacLean, RN, Diane Winans, Dominic T. Moore, PhD, Andrew Dodd, Matthew C. Foster, MD, Don A. Gabriel, MD, PhD, Thomas C. Shea, Jonathan Serody, MD, Hendrik W. van Deventer, MD, Syed Rizvi, Robert Z. Orlowski, M.D., Ph.D., David D. Hurd, MD

Blood (2009) 114 (22): 306.

https://doi.org/10.1182/blood.V114.22.306.306

Published: 2009

Journal Articles

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Deborah J. Kuhn, Qing Chen, Peter M. Voorhees, John S. Strader, Kevin D. Shenk, Congcong M. Sun, Susan D. Demo, Mark K. Bennett, Fijs W. B. van Leeuwen, Asher A. Chanan-Khan, Robert Z. Orlowski

Blood (2007) 110 (9): 3281–3290.

https://doi.org/10.1182/blood-2007-01-065888

Published: 2007

Includes: Supplemental data

Journal Articles

Development of Immunoproteasome-Specific Inhibitors as Novel Anti-Cancer Drugs.

Deborah J. Kuhn, PhD, Peter M. Voorhees, MD, Qing Chen, PhD, John S. Strader, Frank Bruzzese, PhD, Jeffrey P. Ciavarri, PhD, Zhigen Hu, PhD, Robert Z. Orlowski, MD, PhD

Blood (2006) 108 (11): 3458.

https://doi.org/10.1182/blood.V108.11.3458.3458

Published: 2006

Journal Articles

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.

Deborah J. Kuhn, PhD, Qing Chen, PhD, Peter M. Voorhees, MD, John S. Strader, Kevin D. Shenk, PhD, Congcong M. Sun, PhD, Susan D. Demo, PhD, Mark K. Bennett, PhD, Fred W. van Leeuwen, PhD, Robert Z. Orlowski, MD, PhD

Blood (2006) 108 (11): 3461.

https://doi.org/10.1182/blood.V108.11.3461.3461

Published: 2006

Journal Articles

Inhibition of Kinesin Spindle Protein Induces Apoptosis and Overcomes Drug Resistance in Models of Multiple Myeloma.

Qing Chen, PhD, Vishwan Pamarthi, Deborah J. Kuhn, PhD, Peter M. Voorhees, MD, John S. Strader, Robert Z. Orlowski, MD, PhD

Blood (2006) 108 (11): 3425.

https://doi.org/10.1182/blood.V108.11.3425.3425

Published: 2006

Journal Articles

Inhibition of Interleukin-6 Signaling with CNTO328 Sensitizes Multiple Myeloma Cells to Bortezomib and Attenuates Proteasome Inhibitor-Mediated Induction of the Anti-Apoptotic Heat Shock Protein Response.

Peter M. Voorhees, MD, Deborah J. Kuhn, PhD, George W. Small, PhD, John S. Strader, PA, Robert Corringham, MD, Mohamed H. Zaki, MD, PhD, Jeffrey Nemeth, PhD, Robert Z. Orlowski, MD, PhD

Blood (2005) 106 (11): 1574.

https://doi.org/10.1182/blood.V106.11.1574.1574

Published: 2005

Journal Articles

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.

Deborah J. Kuhn, PhD, Peter M. Voorhees, MD, John S. Strader, PA, Kevin D. Shenk, PhD, Congcong M. Sun, PhD, Susan D. Demo, PhD, Mark K. Bennett, PhD, Robert Z. Orlowski, MD, PhD

Blood (2005) 106 (11): 1576.

https://doi.org/10.1182/blood.V106.11.1576.1576

Published: 2005

NARROW

Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Development of Immunoproteasome-Specific Inhibitors as Novel Anti-Cancer Drugs.

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.

Inhibition of Kinesin Spindle Protein Induces Apoptosis and Overcomes Drug Resistance in Models of Multiple Myeloma.

Inhibition of Interleukin-6 Signaling with CNTO328 Sensitizes Multiple Myeloma Cells to Bortezomib and Attenuates Proteasome Inhibitor-Mediated Induction of the Anti-Apoptotic Heat Shock Protein Response.

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Development of Immunoproteasome-Specific Inhibitors as Novel Anti-Cancer Drugs.

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.

Inhibition of Kinesin Spindle Protein Induces Apoptosis and Overcomes Drug Resistance in Models of Multiple Myeloma.

Inhibition of Interleukin-6 Signaling with CNTO328 Sensitizes Multiple Myeloma Cells to Bortezomib and Attenuates Proteasome Inhibitor-Mediated Induction of the Anti-Apoptotic Heat Shock Protein Response.

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only